Publications

The effect of obesity on adipose-derived stromal cells and adipose tissue and their impact on cancer.

Bunnell BA, Martin EC, Matossian MD, Brock CK, Nguyen K, Collins-Burow B, Burow ME.Cancer Metastasis Rev. 2022 Aug 24. doi: 10.1007/s10555-022-10063-1. Online ahead of print.PMID: 35999486

Ceritinib is a novel triple negative breast cancer therapeutic agent.

Dong S, Yousefi H, Savage IV, Okpechi SC, Wright MK, Matossian MD, Collins-Burow BM, Burow ME, Alahari SK.Mol Cancer. 2022 Jun 29;21(1):138. doi: 10.1186/s12943-022-01601-0.PMID: 35768871

Liver Kinase B1 Regulates Remodeling of the Tumor Microenvironment in Triple-Negative Breast Cancer.

King CT, Matossian MD, Savoie JJ, Nguyen K, Wright MK, Byrne CE, Elliott S, Burks HE, Bratton MR, Pashos NC, Bunnell BA, Burow ME, Collins-Burow BM, Martin EC.Front Mol Biosci. 2022 Jun 8;9:847505. doi: 10.3389/fmolb.2022.847505. eCollection 2022.PMID: 35755802

Expression of Novel Kinase MAP3K19 in Various Cancers and Survival Correlations.

Nguyen K, Yousefi H, Cheng T, Magrath J, Hartono AB, Alzoubi M, Hebert K, Brock CK, Wright MK, Byrne CE, Rivera A, Okpechi SC, Matossian MD, Wathieu H, Elliott S, Mondrinos MJ, Lee SB, Collins-Burow BM, Alahari SK, Drewry DH, Burow ME.Front Biosci (Landmark Ed). 2022 Jun 17;27(6):196. doi: 10.31083/j.fbl2706196.PMID: 35748272 Review.

The role of MEK1/2 and MEK5 in melatonin-mediated actions on osteoblastogenesis, osteoclastogenesis, bone microarchitecture, biomechanics, and bone formation.

Munmun F, Mohiuddin OA, Hoang VT, Burow ME, Bunnell BA, Sola VM, Carpentieri AR, Witt-Enderby PA.J Pineal Res. 2022 Jun 8:e12814. doi: 10.1111/jpi.12814. Online ahead of print.PMID: 35674448

MAP3K Family Review and Correlations with Patient Survival Outcomes in Various Cancer Types.

Nguyen K, Tran MN, Rivera A, Cheng T, Windsor GO, Chabot AB, Cavanaugh JE, Collins-Burow BM, Lee SB, Drewry DH, Flaherty PT, Burow ME.Front Biosci (Landmark Ed). 2022 May 23;27(5):167. doi: 10.31083/j.fbl2705167.PMID: 35638434 Review.

Breast Cancer-Stromal Interactions: Adipose-Derived Stromal/Stem Cell Age and Cancer Subtype Mediated Remodeling.

Hamel KM, King CT, Cavalier MB, Liimatta KQ, Rozanski GL, King TA, Lam M, Bingham GC, Byrne CE, Xing D, Collins-Burow BM, Burow ME, Belgodere JA, Bratton MR, Bunnell BA, Martin EC.Stem Cells Dev. 2022 Jul 12. doi: 10.1089/scd.2021.0279. Online ahead of print.PMID: 35579936

Salt-Inducible Kinase 1 is a potential therapeutic target in Desmoplastic Small Round Cell Tumor.

Hartono AB, Kang HJ, Shi L, Phipps W, Ungerleider N, Giardina A, Chen W, Spraggon L, Somwar R, Moroz K, Drewry DH, Burow ME, Flemington E, Ladanyi M, Lee SB.Oncogenesis. 2022 Apr 20;11(1):18. doi: 10.1038/s41389-022-00395-6.PMID: 35443736

Glyceollins Trigger Anti-Proliferative Effects in Hormone-Dependent Aromatase-Inhibitor-Resistant Breast Cancer Cells through the Induction of Apoptosis.

Walker RR, Patel JR, Gupta A, Davidson AM, Williams CC, Payton-Stewart F, Boué SM, Burow ME, Khupse R, Tilghman SL.Int J Mol Sci. 2022 Mar 7;23(5):2887. doi: 10.3390/ijms23052887.PMID: 35270029

Multifunctional profiling of triple-negative breast cancer patient-derived tumoroids for disease modeling.

Cromwell EF, Sirenko O, Nikolov E, Hammer M, Brock CK, Matossian MD, Alzoubi MS, Collins-Burow BM, Burow ME.SLAS Discov. 2022 Apr;27(3):191-200. doi: 10.1016/j.slasd.2022.01.006. Epub 2022 Feb 4.PMID: 35124274

Role of Nischarin in the pathology of diseases: a special emphasis on breast cancer.

Okpechi SC, Yousefi H, Nguyen K, Cheng T, Alahari NV, Collins-Burow B, Burow ME, Alahari SK.Oncogene. 2022 Feb;41(8):1079-1086. doi: 10.1038/s41388-021-02150-4. Epub 2022 Jan 22.PMID: 35064214 Review.

A Role for Adipocytes and Adipose Stem Cells in the Breast Tumor Microenvironment and Regenerative Medicine.

Brock CK, Hebert KL, Artiles M, Wright MK, Cheng T, Windsor GO, Nguyen K, Alzoubi MS, Collins-Burow BM, Martin EC, Lau FH, Bunnell BA, Burow ME.Front Physiol. 2021 Nov 29;12:751239. doi: 10.3389/fphys.2021.751239. eCollection 2021.PMID: 34912237

In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types.

Matossian MD, Chang T, Wright MK, Burks HE, Elliott S, Sabol RA, Wathieu H, Windsor GO, Alzoubi MS, King CT, Bursavich JB, Ham AM, Savoie JJ, Nguyen K, Baddoo M, Flemington E, Sirenko O, Cromwell EF, Hebert KL, Lau F, Izadpanah R, Brown H, Sinha S, Zabaleta J, Riker AI, Moroz K, Miele L, Zea AH, Ochoa A, Bunnell BA, Collins-Burow BM, Martin EC, Burow ME.Clin Transl Oncol. 2022 Jan;24(1):127-144. doi: 10.1007/s12094-021-02677-8. Epub 2021 Aug 9.PMID: 34370182

ZEB2 regulates endocrine therapy sensitivity and metastasis in luminal a breast cancer cells through a non-canonical mechanism.

Burks HE, Matossian MD, Rhodes LV, Phamduy T, Elliott S, Buechlein A, Rusch DB, Miller DFB, Nephew KP, Chrisey D, Collins-Burow BM, Burow ME.Breast Cancer Res Treat. 2021 Aug;189(1):25-37. doi: 10.1007/s10549-021-06256-x. Epub 2021 Jul 6.PMID: 34231077

Constitutive activation of MEK5 promotes a mesenchymal and migratory cell phenotype in triple negative breast cancer.

Matossian MD, Hoang VT, Burks HE, La J, Elliott S, Brock C, Rusch DB, Buechlein A, Nephew KP, Bhatt A, Cavanaugh JE, Flaherty PT, Collins-Burow BM, Burow ME.Oncoscience. 2021 May 18;8:64-71. doi: 10.18632/oncoscience.535. eCollection 2021.PMID: 34026925

Correction: Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor.

Chang TC, Matossian MD, Elliott S, Burks HE, Sabol RA, Ucar DA, Wathieu H, Zabaleta J, Valle LD, Gill S, Martin E, Riker AI, Miele L, Bunnell BA, Burow ME, Collins-Burow BM.PLoS One. 2021 Apr 29;16(4):e0251106. doi: 10.1371/journal.pone.0251106. eCollection 2021.PMID: 33914835

Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulation.

Hoang VT, Matossian MD, La J, Hoang K, Ucar DA, Elliott S, Burks HE, Wright TD, Patel S, Bhatt A, Phamduy T, Chrisey D, Buechlein A, Rusch DB, Nephew KP, Anbalagan M, Rowan B, Cavanaugh JE, Flaherty PT, Miele L, Collins-Burow BM, Burow ME.J Cell Biochem. 2021 Aug;122(8):835-850. doi: 10.1002/jcb.29916. Epub 2021 Apr 20.PMID: 33876843

Evaluation of Extracellular Matrix Composition to Improve Breast Cancer Modeling.

Byrne CE, Decombe JB, Bingham GC, Remont J, Miller LG, Khalif L, King CT, Hamel K, Bunnell BA, Burow ME, Martin EC.Tissue Eng Part A. 2021 Apr;27(7-8):500-511. doi: 10.1089/ten.TEA.2020.0364.PMID: 33797977

Quantifying Breast Cancer-Driven Fiber Alignment and Collagen Deposition in Primary Human Breast Tissue.

Gurrala R, Byrne CE, Brown LM, Tiongco RFP, Matossian MD, Savoie JJ, Collins-Burow BM, Burow ME, Martin EC, Lau FH.Front Bioeng Biotechnol. 2021 Mar 15;9:618448. doi: 10.3389/fbioe.2021.618448. eCollection 2021.PMID: 33791282

Patient-Derived Xenografts as an Innovative Surrogate Tumor Model for the Investigation of Health Disparities in Triple Negative Breast Cancer.

Matossian MD, Giardina AA, Wright MK, Elliott S, Loch MM, Nguyen K, Zea AH, Lau FH, Moroz K, Riker AI, Jones SD, Martin EC, Bunnell BA, Miele L, Collins-Burow BM, Burow ME.Womens Health Rep (New Rochelle). 2020 Sep 24;1(1):383-392. doi: 10.1089/whr.2020.0037. eCollection 2020.PMID: 33786503. Review.

Application of a small molecule inhibitor screen approach to identify CXCR4 downstream signaling pathways that promote a mesenchymal and fulvestrant-resistant phenotype in breast cancer cells.

Matossian MD, Elliott S, Rhodes LV, Martin EC, Hoang VT, Burks HE, Zuercher WJ, Drewry DH, Collins-Burow BM, Burow ME.Oncol Lett. 2021 May;21(5):380. doi: 10.3892/ol.2021.12641. Epub 2021 Mar 16.PMID: 33777204

Diverse and converging roles of ERK1/2 and ERK5 pathways on mesenchymal to epithelial transition in breast cancer.

Bhatt AB, Wright TD, Barnes V, Chakrabarty S, Matossian MD, Lexner E, Ucar DA, Miele L, Flaherty PT, Burow ME, Cavanaugh JE.Transl Oncol. 2021 Jun;14(6):101046. doi: 10.1016/j.tranon.2021.101046. Epub 2021 Mar 21.PMID: 33761370 .

Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review.

Matossian MD, Wells CI, Zuercher WJ, Collins-Burow BM, Drewry DH, Burow ME.Curr Med Chem. 2021 Mar 21. doi: 10.2174/0929867328666210322101749. Online ahead of print.PMID: 33749548

Molecular Mechanisms of Epithelial to Mesenchymal Transition Regulated by ERK5 Signaling.

Bhatt AB, Patel S, Matossian MD, Ucar DA, Miele L, Burow ME, Flaherty PT, Cavanaugh JE.Biomolecules. 2021 Jan 29;11(2):183. doi: 10.3390/biom11020183.PMID: 33572742. Review.

Bioprinting on Live Tissue for Investigating Cancer Cell Dynamics.

Suarez-Martinez AD, Sole-Gras M, Dykes SS, Wakefield ZR, Bauer K, Majbour D, Bundy A, Pampo C, Burow ME, Siemann DW, Huang Y, Murfee WL.Tissue Eng Part A. 2021 Apr;27(7-8):438-453. doi: 10.1089/ten.TEA.2020.0190. Epub 2020 Nov 18.PMID: 33059528

Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor.

Chang TC, Matossian MD, Elliott S, Burks HE, Sabol RA, Ucar DA, Wathieu H, Zabaleta J, Del Valle L, Gill S, Martin E, Riker AI, Miele L, Bunnell BA, Burow ME, Collins-Burow BM.PLoS One. 2020 Oct 9;15(10):e0226464. doi: 10.1371/journal.pone.0226464. eCollection 2020.PMID: 33035223

ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer.

Hoang VT, Matossian MD, Ucar DA, Elliott S, La J, Wright MK, Burks HE, Perles A, Hossain F, King CT, Browning VE, Bursavich J, Fang F, Del Valle L, Bhatt AB, Cavanaugh JE, Flaherty PT, Anbalagan M, Rowan BG, Bratton MR, Nephew KP, Miele L, Collins-Burow BM, Martin EC, Burow ME.Front Oncol. 2020 Aug 3;10:1164. doi: 10.3389/fonc.2020.01164. eCollection 2020.PMID: 32850332

A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathways.

Matossian MD, Burks HE, Elliott S, Hoang VT, Zuercher WJ, Wells C, Drewry DH, Kapadia N, Chang T, Yan T, Windsor GO, Nguyen K, Fang F, Nephew KP, Buechlein A, Rusch DB, Sabol RA, Ucar DA, Zabaleta J, Miele L, Bunnell BA, Collins-Burow BM, Burow ME.Anticancer Drugs. 2020 Sep;31(8):759-775. doi: 10.1097/CAD.0000000000000962.PMID: 32796402

Targeting TRAF3IP2, Compared to Rab27, is More Effective in Suppressing the Development and Metastasis of Breast Cancer.

Alt EU, Wörner PM, Pfnür A, Ochoa JE, Schächtele DJ, Barabadi Z, Lang LM, Srivastav S,Burow ME, Chandrasekar B, Izadpanah R.Sci Rep. 2020 Jun 1;10(1):8834. doi: 10.1038/s41598-020-64781-z.PMID: 32483202

Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.

Wright TD, Raybuck C, Bhatt A, Monlish D, Chakrabarty S, Wendekier K, Gartland N, Gupta M, Burow ME, Flaherty PT, Cavanaugh JE.J Cell Biochem. 2020 Feb;121(2):1156-1168. doi: 10.1002/jcb.29350. Epub 2019 Aug 28.PMID: 31464004

Novel Diphenylamine Analogs Induce Mesenchymal to Epithelial Transition in Triple Negative Breast Cancer.

Bhatt AB, Gupta M, Hoang VT, Chakrabarty S, Wright TD, Elliot S, Chopra IK, Monlish D, Anna K, Burow ME, Cavanaugh JE, Flaherty PT.Front Oncol. 2019 Jul 30;9:672. doi: 10.3389/fonc.2019.00672. eCollection 2019.PMID: 31417863

Pharmacological, Mechanistic, and Pharmacokinetic Assessment of Novel Melatonin-Tamoxifen Drug Conjugates as Breast Cancer Drugs.

Hasan M, Marzouk MA, Adhikari S, Wright TD, Miller BP, Matossian MD, Elliott S, Wright M, Alzoubi M, Collins-Burow BM, Burow ME, Holzgrabe U, Zlotos DP, Stratford RE, Witt-Enderby PA.Mol Pharmacol. 2019 Aug;96(2):272-296. doi: 10.1124/mol.119.116202. Epub 2019 Jun 20.PMID: 31221824

Leptin produced by obesity-altered adipose stem cells promotes metastasis but not tumorigenesis of triple-negative breast cancer in orthotopic xenograft and patient-derived xenograft models.

Sabol RA, Bowles AC, Côté A, Wise R, O’Donnell B, Matossian MD, Hossain FM, Burks HE, Del Valle L, Miele L, Collins-Burow BM, Burow ME, Bunnell BA.Breast Cancer Res. 2019 May 22;21(1):67. doi: 10.1186/s13058-019-1153-9.PMID: 31118047

Obesity-Altered Adipose Stem Cells Promote ER⁺ Breast Cancer Metastasis through Estrogen Independent Pathways.

Sabol RA, Beighley A, Giacomelli P, Wise RM, Harrison MAA, O’Donnnell BA, Sullivan BN, Lampenfeld JD, Matossian MD, Bratton MR, Wang G, Collins-Burow BM, Burow ME, Bunnell BA.Int J Mol Sci. 2019 Mar 20;20(6):1419. doi: 10.3390/ijms20061419.PMID: 30897853

Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model.

Matossian MD, Burks HE, Elliott S, Hoang VT, Bowles AC, Sabol RA, Wahba B, Anbalagan M, Rowan B, Abazeed ME, Bunnell BA, Moroz K, Miele L, Rhodes LV, Jones SD, Martin EC, Collins-Burow BM, Burow ME.BMC Cancer. 2019 Mar 7;19(1):205. doi: 10.1186/s12885-019-5401-2.PMID: 30845999

Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.

Zhou W, Guo S, Liu M, Burow ME, Wang G.Curr Med Chem. 2019;26(17):3026-3041. doi: 10.2174/0929867324666170830111531.PMID: 28875842

Notch Signaling Regulates Mitochondrial Metabolism and NF-κB Activity in Triple-Negative Breast Cancer Cells via IKKα-Dependent Non-canonical Pathways.

Hossain F, Sorrentino C, Ucar DA, Peng Y, Matossian M, Wyczechowska D, Crabtree J, Zabaleta J, Morello S, Del Valle L, Burow M, Collins-Burow B, Pannuti A, Minter LM, Golde TE, Osborne BA, Miele L.Front Oncol. 2018 Dec 4;8:575. doi: 10.3389/fonc.2018.00575. eCollection 2018.PMID: 30564555

Loss of Forkhead Box O3 Facilitates Inflammatory Colon Cancer: Transcriptome Profiling of the Immune Landscape and Novel Targets.

Penrose HM, Cable C, Heller S, Ungerleider N, Nakhoul H, Baddoo M, Hartono AB, Lee SB, Burow ME, Flemington EF, Crawford SE, Savkovic SD.Cell Mol Gastroenterol Hepatol. 2019;7(2):391-408. doi: 10.1016/j.jcmgh.2018.10.003. Epub 2018 Oct 13.PMID: 30718226

Engineering Breast Cancer Microenvironments and 3D Bioprinting.

Belgodere JA, King CT, Bursavich JB, Burow ME, Martin EC, Jung JP.Front Bioeng Biotechnol. 2018 May 24;6:66. doi: 10.3389/fbioe.2018.00066. eCollection 2018.PMID: 29881724

Structure activity relationships of anthranilic acid-based compounds on cellular and in vivo mitogen activated protein kinase-5 signaling pathways.

Chakrabarty S, Monlish DA, Gupta M, Wright TD, Hoang VT, Fedak M, Chopra I, Flaherty PT, Madura J, Mannepelli S, Burow ME, Cavanaugh JE.Bioorg Med Chem Lett. 2018 Jul 15;28(13):2294-2301. doi: 10.1016/j.bmcl.2018.05.029. Epub 2018 May 20.PMID: 29803729

Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model.

Matossian MD, Burks HE, Elliott S, Hoang VT, Bowles AC, Sabol RA, Bunnell BA, Martin EC, Burow ME, Collins-Burow BM.Oncoscience. 2018 Apr 29;5(3-4):99-108. doi: 10.18632/oncoscience.412. eCollection 2018 Mar.PMID: 29854878

A novel patient-derived xenograft model for claudin-low triple-negative breast cancer.

Matossian MD, Burks HE, Bowles AC, Elliott S, Hoang VT, Sabol RA, Pashos NC, O’Donnell B, Miller KS, Wahba BM, Bunnell BA, Moroz K, Zea AH, Jones SD, Ochoa AC, Al-Khami AA, Hossain F, Riker AI, Rhodes LV, Martin EC, Miele L, Burow ME, Collins-Burow BM.Breast Cancer Res Treat. 2018 Jun;169(2):381-390. doi: 10.1007/s10549-018-4685-2. Epub 2018 Feb 1.PMID: 29392581

Biological effects of melatonin on osteoblast/osteoclast cocultures, bone, and quality of life: Implications of a role for MT2 melatonin receptors, MEK1/2, and MEK5 in melatonin-mediated osteoblastogenesis.

Maria S, Samsonraj RM, Munmun F, Glas J, Silvestros M, Kotlarczyk MP, Rylands R, Dudakovic A, van Wijnen AJ, Enderby LT, Lassila H, Dodda B, Davis VL, Balk J, Burow M, Bunnell BA, Witt-Enderby PA.J Pineal Res. 2018 Apr;64(3):10.1111/jpi.12465. doi: 10.1111/jpi.12465. Epub 2018 Jan 17.PMID: 29285799

ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models.

Guo S, Zhang C, Bratton M, Mottamal M, Liu J, Ma P, Zheng S, Zhong Q, Yang L, Wiese TE, Wu Y, Ellis MJ, Matossian M, Burow ME, Miele L, Houtman R, Wang G.Oncotarget. 2018 Jan 8;9(6):6924-6937. doi: 10.18632/oncotarget.24023. eCollection 2018 Jan 23.PMID: 29467940

Mirna biogenesis pathway is differentially regulated during adipose derived stromal/stem cell differentiation.

Martin EC, Qureshi AT, Llamas CB, Burow ME, King AG, Lee OC, Dasa V, Freitas MA, Forsberg JA, Elster EA, Davis TA, Gimble JM.

Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes.

Matossian MD, Elliott S, Hoang VT, Burks HE, Phamduy TB, Chrisey DB, Zuercher WJ, Drewry DH, Wells C, Collins-Burow B, Burow ME.PLoS One. 2017 Aug 3;12(8):e0177802. doi: 10.1371/journal.pone.0177802. eCollection 2017.PMID: 28771473

Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.

Anbalagan M, Sheng M, Fleischer B, Zhang Y, Gao Y, Hoang V, Matossian M, Burks HE, Burow ME, Collins-Burow BM, Hangauer D, Rowan BG.Mol Cancer Res. 2017 Nov;15(11):1491-1502. doi: 10.1158/1541-7786.MCR-16-0297-T. Epub 2017 Jul 27.PMID: 28751463

Glycinol enhances osteogenic differentiation and attenuates the effects of age on mesenchymal stem cells.

Strong AL, Jones RB Jr, Glowacki J, Boue SM, Burow ME, Bunnell BA.Regen Med. 2017 Jul;12(5):513-524. doi: 10.2217/rme-2016-0148. Epub 2017 Jul 18.PMID: 28718749

Laser direct-write based fabrication of a spatially-defined, biomimetic construct as a potential model for breast cancer cell invasion into adipose tissue.

Vinson BT, Phamduy TB, Shipman J, Riggs B, Strong AL, Sklare SC, Murfee WL, Burow ME, Bunnell BA, Huang Y, Chrisey DB.Biofabrication. 2017 May 11;9(2):025013. doi: 10.1088/1758-5090/aa6bad.PMID: 28382922

Osteoinductive effects of glyceollins on adult mesenchymal stromal/stem cells from adipose tissue and bone marrow.

Bateman ME, Strong AL, Hunter RS, Bratton MR, Komati R, Sridhar J, Riley KE, Wang G, Hayes DJ, Boue SM, Burow ME, Bunnell BA.Phytomedicine. 2017 Apr 15;27:39-51. doi: 10.1016/j.phymed.2017.02.003. Epub 2017 Feb 14.PMID: 28314478

Oncogenic signaling of MEK5-ERK5.

Hoang VT, Yan TJ, Cavanaugh JE, Flaherty PT, Beckman BS, Burow ME.Cancer Lett. 2017 Apr 28;392:51-59. doi: 10.1016/j.canlet.2017.01.034. Epub 2017 Jan 30.PMID: 28153789

The Effects of Endocrine Disruptors on Adipogenesis and Osteogenesis in Mesenchymal Stem Cells: A Review.

Bateman ME, Strong AL, McLachlan JA, Burow ME, Bunnell BA.Front Endocrinol (Lausanne). 2017 Jan 9;7:171. doi: 10.3389/fendo.2016.00171. eCollection 2016.PMID: 28119665

Obesity Enhances the Conversion of Adipose-Derived Stromal/Stem Cells into Carcinoma-Associated Fibroblast Leading to Cancer Cell Proliferation and Progression to an Invasive Phenotype.

Strong AL, Pei DT, Hurst CG, Gimble JM, Burow ME, Bunnell BA.Stem Cells Int. 2017;2017:9216502. doi: 10.1155/2017/9216502. Epub 2017 Dec 17.PMID: 29527228

MicroRNA-335-5p and -3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance.

Martin EC, Conger AK, Yan TJ, Hoang VT, Miller DF, Buechlein A, Rusch DB, Nephew KP, Collins-Burow BM, Burow ME.FEBS Lett. 2017 Jan;591(2):382-392. doi: 10.1002/1873-3468.12538. Epub 2017 Jan 12.PMID: 28008602

Endocrine disruptors and the tumor microenvironment: A new paradigm in breast cancer biology.

Burks H, Pashos N, Martin E, Mclachlan J, Bunnell B, Burow M.Mol Cell Endocrinol. 2017 Dec 5;457:13-19. doi: 10.1016/j.mce.2016.12.010. Epub 2016 Dec 22.PMID: 28012841

Argonaute 2 Expression Correlates with a Luminal B Breast Cancer Subtype and Induces Estrogen Receptor Alpha Isoform Variation.

Conger AK, Martin EC, Yan TJ, Rhodes LV, Hoang VT, La J, Anbalagan M, Burks HE, Rowan BG, Nephew KP, Collins-Burow BM, Burow ME.Noncoding RNA. 2016 Sep 21;2(3):8. doi: 10.3390/ncrna2030008.PMID: 29657266

Induction of HOXA9 expression in three-dimensional organotypic culture of the Claudin-low breast cancer cells.

Li M, Li X, Zhuang Y, Wang Y, Burow ME, Collins-Burow B, Xue M, Song C, Shan B.Oncotarget. 2016 Aug 9;7(32):51503-51514. doi: 10.18632/oncotarget.10491.PMID: 27409175

Laser Direct-Write Onto Live Tissues: A Novel Model for Studying Cancer Cell Migration.

Burks HE, Phamduy TB, Azimi MS, Saksena J, Burow ME, Collins-Burow BM, Chrisey DB, Murfee WL.J Cell Physiol. 2016 Nov;231(11):2333-8. doi: 10.1002/jcp.25363. Epub 2016 Mar 15.PMID: 26923437

Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1.

Carriere PP, Llopis SD, Naiki AC, Nguyen G, Phan T, Nguyen MM, Preyan LC, Yearby L, Pratt J, Burks H, Davenport IR, Nguyen TA, Parker-Lemieux K, Payton-Stewart F, Williams CC, Boué SM, Burow ME, Collins-Burow B, Hilliard A, Davidson AM, Tilghman SL.

Int J Environ Res Public Health. 2015 Dec 22;13(1):ijerph13010010. doi: 10.3390/ijerph13010010.

A novel gastrointestinal microbiome modulator from soy pods reduces absorption of dietary fat in mice.

Boué S, Fortgang I, Levy RJ Jr, Bhatnagar D, Burow M, Fahey G, Heiman ML.

Obesity (Silver Spring). 2016 Jan;24(1):87-95. doi: 10.1002/oby.21197. Epub 2015 Nov 20.

Regulation of triple-negative breast cancer cell metastasis by the tumor-suppressor liver kinase B1.

Rhodes LV, Tate CR, Hoang VT, Burks HE, Gilliam D, Martin EC, Elliott S, Miller DB, Buechlein A, Rusch D, Tang H, Nephew KP, Burow ME, Collins-Burow BM.

Oncogenesis. 2015 Oct 5;4:e168. doi: 10.1038/oncsis.2015.27.

Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers.

Strong AL, Ohlstein JF, Biagas BA, Rhodes LV, Pei DT, Tucker HA, Llamas C, Bowles AC, Dutreil MF, Zhang S, Gimble JM, Burow ME, Bunnell BA.

Breast Cancer Res. 2015 Aug 19;17:112. doi: 10.1186/s13058-015-0622-z.

Printing cancer cells into intact microvascular networks: a model for investigating cancer cell dynamics during angiogenesis.

Phamduy TB, Sweat RS, Azimi MS, Burow ME, Murfee WL, Chrisey DB.

Integr Biol (Camb). 2015 Sep;7(9):1068-78. doi: 10.1039/c5ib00151j. Epub 2015 Jul 20.

Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.

Rhodes LV, Martin EC, Segar HC, Miller DF, Buechlein A, Rusch DB, Nephew KP, Burow ME, Collins-Burow BM.

Oncotarget. 2015 Jun 30;6(18):16638-52.

Glyceollin, a novel regulator of mTOR/p70S6 in estrogen receptor positive breast cancer.

Bratton MR, Martin EC, Elliott S, Rhodes LV, Collins-Burow BM, McLachlan JA, Wiese TE, Boue SM, Burow ME.

J Steroid Biochem Mol Biol. 2015 Jun;150:17-23. doi: 10.1016/j.jsbmb.2014.12.014. Epub 2015 Mar 12.

miR-155 induced transcriptome changes in the MCF-7 breast cancer cell line leads to enhanced mitogen activated protein kinase signaling.

Martin EC, Krebs AE, Burks HE, Elliott S, Baddoo M, Collins-Burow BM, Flemington EK, Burow ME.

Genes Cancer. 2014 Sep;5(9-10):353-64.

Elevated expression of long intergenic non-coding RNA HOTAIR in a basal-like variant of MCF-7 breast cancer cells.

Zhuang Y, Nguyen HT, Burow ME, Zhuo Y, El-Dahr SS, Yao X, Cao S, Flemington EK, Nephew KP, Fang F, Collins-Burow B, Rhodes LV, Yu Q, Jayawickramarajah J, Shan B.

Mol Carcinog. 2015 Dec;54(12):1656-67. doi: 10.1002/mc.22237. Epub 2014 Oct 18.

microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity.

Martin EC, Rhodes LV, Elliott S, Krebs AE, Nephew KP, Flemington EK, Collins-Burow BM, Burow ME.

Mol Cancer. 2014 Oct 6;13:229. doi: 10.1186/1476-4598-13-229.

Novel daidzein analogs enhance osteogenic activity of bone marrow-derived mesenchymal stem cells and adipose-derived stromal/stem cells through estrogen receptor dependent and independent mechanisms.

Strong AL, Ohlstein JF, Jiang Q, Zhang Q, Zheng S, Boue SM, Elliott S, Gimble JM, Burow ME, Wang G, Bunnell BA.

Stem Cell Res Ther. 2014 Aug 28;5(4):105. doi: 10.1186/scrt493.

Bisphenol A enhances adipogenic differentiation of human adipose stromal/stem cells.

Ohlstein JF, Strong AL, McLachlan JA, Gimble JM, Burow ME, Bunnell BA.

J Mol Endocrinol. 2014 Dec;53(3):345-53. doi: 10.1530/JME-14-0052. Epub 2014 Aug 20.

Effects of the endocrine-disrupting chemical DDT on self-renewal and differentiation of human mesenchymal stem cells.

Strong AL, Shi Z, Strong MJ, Miller DF, Rusch DB, Buechlein AM, Flemington EK, McLachlan JA, Nephew KP, Burow ME, Bunnell BA.

Environ Health Perspect. 2015 Jan;123(1):42-8. doi: 10.1289/ehp.1408188. Epub 2014 Jul 11.

Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival.

Gestaut MM, Antoon JW, Burow ME, Beckman BS.

Pharmacol Rep. 2014 Feb;66(1):174-8. doi: 10.1016/j.pharep.2013.08.014. Epub 2014 Feb 3.

Design, synthesis, and osteogenic activity of daidzein analogs on human mesenchymal stem cells.

Strong AL, Jiang Q, Zhang Q, Zheng S, Boue SM, Elliott S, Burow ME, Bunnell BA, Wang G.

ACS Med Chem Lett. 2013 Dec 10;5(2):143-8. doi: 10.1021/ml400397k. eCollection 2014 Feb 13.

Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.

Rhodes LV, Tate CR, Segar HC, Burks HE, Phamduy TB, Hoang V, Elliott S, Gilliam D, Pounder FN, Anbalagan M, Chrisey DB, Rowan BG, Burow ME, Collins-Burow BM.

Breast Cancer Res Treat. 2014 Jun;145(3):593-604. doi: 10.1007/s10549-014-2979-6. Epub 2014 May 9.

MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.

Antoon JW, Martin EC, Lai R, Salvo VA, Tang Y, Nitzchke AM, Elliott S, Nam SY, Xiong W, Rhodes LV, Collins-Burow B, David O, Wang G, Shan B, Beckman BS, Nephew KP, Burow ME.

PLoS One. 2013 Aug 9;8(8):e69291. doi: 10.1371/journal.pone.0069291. eCollection 2013.

Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy.

Strong MJ, Xu G, Coco J, Baribault C, Vinay DS, Lacey MR, Strong AL, Lehman TA, Seddon MB, Lin Z, Concha M, Baddoo M, Ferris M, Swan KF, Sullivan DE, Burow ME, Taylor CM, Flemington EK.

PLoS Pathog. 2013;9(5):e1003341. doi: 10.1371/journal.ppat.1003341. Epub 2013 May 9.

Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition.

Antoon JW, Nitzchke AM, Martin EC, Rhodes LV, Nam S, Wadsworth S, Salvo VA, Elliott S, Collins-Burow B, Nephew KP, Burow ME.

Int J Oncol. 2013 Apr;42(4):1139-50. doi: 10.3892/ijo.2013.1814. Epub 2013 Feb 8.

Insulin-like growth factor-1 signaling regulates miRNA expression in MCF-7 breast cancer cell line.

Martin EC, Bratton MR, Zhu Y, Rhodes LV, Tilghman SL, Collins-Burow BM, Burow ME.

PLoS One. 2012;7(11):e49067. doi: 10.1371/journal.pone.0049067. Epub 2012 Nov 30.

Preferential star strand biogenesis of pre-miR-24-2 targets PKC-alpha and suppresses cell survival in MCF-7 breast cancer cells.

Martin EC, Elliott S, Rhodes LV, Antoon JW, Fewell C, Zhu Y, Driver JL, Jodari-Karimi M, Taylor CW, Flemington EK, Beckman BS, Collins-Burow BM, Burow ME.

Mol Carcinog. 2014 Jan;53(1):38-48. doi: 10.1002/mc.21946. Epub 2012 Aug 21.

Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer.

Antoon JW, White MD, Driver JL, Burow ME, Beckman BS.

Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance.

Antoon JW, Lai R, Struckhoff AP, Nitschke AM, Elliott S, Martin EC, Rhodes LV, Yoon NS, Salvo VA, Shan B, Beckman BS, Nephew KP, Burow ME.

Sci Rep. 2012;2:539. doi: 10.1038/srep00539. Epub 2012 Jul 27.

Inhibition of p38-MAPK alters SRC coactivation and estrogen receptor phosphorylation.

Antoon JW, Bratton MR, Guillot LM, Wadsworth S, Salvo VA, Burow ME.

Cancer Biol Ther. 2012 Sep;13(11):1026-33. doi: 10.4161/cbt.20992. Epub 2012 Jul 24.

Antiestrogenic activity of flavonoid phytochemicals mediated via the c-Jun N-terminal protein kinase pathway. Cell-type specific regulation of estrogen receptor alpha.

Collins-Burow BM, Antoon JW, Frigo DE, Elliott S, Weldon CB, Boue SM, Beckman BS, Curiel TJ, Alam J, McLachlan JA, Burow ME.

J Steroid Biochem Mol Biol. 2012 Oct;132(1-2):186-93. doi: 10.1016/j.jsbmb.2012.05.004. Epub 2012 May 24.

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.

Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, Collins-Burow BM.

Breast Cancer Res. 2012 May 21;14(3):R79.

The organochlorine o,p’-DDT plays a role in coactivator-mediated MAPK crosstalk in MCF-7 breast cancer cells.

Bratton MR, Frigo DE, Segar HC, Nephew KP, McLachlan JA, Wiese TE, Burow ME.

Environ Health Perspect. 2012 Sep;120(9):1291-6. doi: 10.1289/ehp.1104296. Epub 2012 May 18.

The microRNA expression associated with morphogenesis of breast cancer cells in three-dimensional organotypic culture.

Nguyen HT, Li C, Lin Z, Zhuang Y, Flemington EK, Burow ME, Lin Y, Shan B.

Oncol Rep. 2012 Jul;28(1):117-26. doi: 10.3892/or.2012.1764. Epub 2012 Apr 19.

Gαo potentiates estrogen receptor α activity via the ERK signaling pathway.

Bratton MR, Antoon JW, Duong BN, Frigo DE, Tilghman S, Collins-Burow BM, Elliott S, Tang Y, Melnik LI, Lai L, Alam J, Beckman BS, Hill SM, Rowan BG, McLachlan JA, Burow ME.

J Endocrinol. 2012 Jul;214(1):45-54. doi: 10.1530/JOE-12-0097. Epub 2012 May 4.

Dual inhibition of sphingosine kinase isoforms ablates TNF-induced drug resistance.

Antoon JW, White MD, Burow ME, Beckman BS.

Oncol Rep. 2012 Jun;27(6):1779-86. doi: 10.3892/or.2012.1743. Epub 2012 Mar 27.

Environmental signaling and reproduction: a comparative biological and chemical perspective.

McLachlan JA, Tilghman SL, Burow ME, Bratton MR.

Mol Cell Endocrinol. 2012 May 6;354(1-2):60-2. doi: 10.1016/j.mce.2011.11.028. Epub 2011 Dec 8. Review.

MEK5/ERK5 pathway: the first fifteen years.

Drew BA, Burow ME, Beckman BS.

Biochim Biophys Acta. 2012 Jan;1825(1):37-48. doi: 10.1016/j.bbcan.2011.10.002. Epub 2011 Oct 13. Review.

The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells.

Rhodes LV, Nitschke AM, Segar HC, Martin EC, Driver JL, Elliott S, Nam SY, Li M, Nephew KP, Burow ME, Collins-Burow BM.

Oncol Rep. 2012 Jan;27(1):10-6. doi: 10.3892/or.2011.1488. Epub 2011 Oct 4.

Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells.

Rhodes LV, Bratton MR, Zhu Y, Tilghman SL, Muir SE, Salvo VA, Tate CR, Elliott S, Nephew KP, Collins-Burow BM, Burow ME.

Exp Cell Res. 2011 Nov 1;317(18):2573-81. doi: 10.1016/j.yexcr.2011.08.016. Epub 2011 Aug 30.

^{Pharmacological Inhibition of Sphingosine Kinase Isoforms Alters Estrogen Receptor Signaling in Human Breast Cancer.}^{Antoon JW, Meacham WD, Bratton MR, Slaughter EM, Rhodes LV, Ashe HB, Wiese TE, Burow ME, Beckman BS.}^{J Mol Endocrinol}^{. 2011 Feb 14.} ^{Targeting NF-ĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2.} ^{Antoon JW, White MD, Slaughter EM, Davis JL, Khalili HS, Elliott S, Smith CD, Burow ME, Beckman BS.} ^{Cancer Biol Ther}^{. 2011 Apr 1;11(7).} ^{Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway.} ^{Mao L, Yuan L, Slakey LM, Jones FE, Burow ME, Hill SM.} ^{Breast Cancer Res}^{. 2010;12(6):R107.} ^{Estrogenic and antiestrogenic activities of phytoalexins from red kidney bean (Phaseolus vulgaris L.).} ^{Boué SM, Burow ME, Wiese TE, Shih BY, Elliott S, Carter-Wientjes CH, McLachlan JA, Bhatnagar D.} ^{J Agric Food Chem}^{. 2011 Jan 12;59(1):112-20.} ^{Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.} ^{Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, Horton LW, Zaja-Milatovic S, Collins-Burow BM, Wadsworth S, Beckman BS, Wood CE, Fuqua SA, Nephew KP, Dent P, Worthylake RA, Curiel TJ, Hung MC, Richmond A, Burow ME.} ^{Cancer Res}^{. 2011 Jan 15;71(2):603-13} ^{Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk.} ^{Rhodes LV, Antoon JW, Muir SE, Elliott S, Beckman BS, Burow ME.} ^{MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways.} ^{Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM, Nephew KP.} ^Oncogene^{. 2010 Nov 8} ^{Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors.} ^{Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, Jones FE.} ^{Carcinogenesis}^{. 2010 Dec;31(12):2049-57.} ^{Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640.} ^{Antoon JW, White MD, Meacham WD, Slaughter EM, Muir SE, Elliott S, Rhodes LV, Ashe HB, Wiese TE, Smith CD, Burow ME, Beckman BS.} ^{Endocrinology}^{. 2010 Nov;151(11):5124-35} ^{Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells.} ^{Jiang Q, Payton-Stewart F, Elliott S, Driver J, Rhodes LV, Zhang Q, Zheng S, Bhatnagar D, Boue SM, Collins-Burow BM, Sridhar J, Stevens C, McLachlan JA, Wiese TE, Burow ME, Wang G.} ^{J Med Chem}^{. 2010 Aug 26;53(16):6153-63.} ^{Regulation of ERalpha-mediated transcription of Bcl-2 by PI3K-AKT crosstalk: implications for breast cancer cell survival.} ^{Bratton MR, Duong BN, Elliott S, Weldon CB, Beckman BS, McLachlan JA, Burow ME.} ^{Int J Oncol}^{. 2010 Sep;37(3):541-50.} ^{Human mesenchymal stem cells as mediators of breast carcinoma tumorigenesis and progression.} ^{Rhodes LV, Burow ME.} ^{ScientificWorldJournal}^{. 2010 Jun 15;10:1084-7} ^{Glyceollin I enantiomers distinctly regulate ER-mediated gene expression.} ^{Payton-Stewart F, Khupse RS, Boué SM, Elliott S, Zimmermann MC, Skripnikova EV, Ashe H, Tilghman SL, Beckman BS, Cleveland TE, McLachlan JA, Bhatnagar D, Wiese TE, Erhardt P, Burow ME.} ^Steroids^{. 2010 Dec;75(12):870-8. Epub 2010 May 21.} ^{Systems genetics analyses predict a transcription role for P2P-R: molecular confirmation that P2P-R is a transcriptional co-repressor.} ^{Peidis P, Giannakouros T, Burow ME, Williams RW, Scott RE.} ^{BMC Syst Biol}^{. 2010 Feb 25;4:14.} ^{Requirement of a novel splicing variant of human histone deacetylase 6 for TGF-beta1-mediated gene activation.} ^{Zhuang Y, Nguyen HT, Lasky JA, Cao S, Li C, Hu J, Guo X, Burow ME, Shan B.} ^{Biochem Biophys Res Commun}^{. 2010 Feb 19;392(4):608-13.} ^{Dynamic regulation of ROCK in tumor cells controls CXCR4-driven adhesion events.} ^{Struckhoff AP, Vitko JR, Rana MK, Davis CT, Foderingham KE, Liu CH, Vanhoy-Rhodes L, Elliott S, Zhu Y, Burow M, Worthylake RA.} ^{J Cell Sci}^{. 2010 Feb 1;123(Pt 3):401-12} ^{Glyceollin I, a novel antiestrogenic phytoalexin isolated from activated soy.} ^{Zimmermann MC, Tilghman SL, Boué SM, Salvo VA, Elliott S, Williams KY, Skripnikova EV, Ashe H, Payton-Stewart F, Vanhoy-Rhodes L, Fonseca JP, Corbitt C, Collins-Burow BM, Howell MH, Lacey M, Shih BY, Carter-Wientjes C, Cleveland TE, McLachlan JA, Wiese TE, Beckman BS, Burow ME.} ^{J Pharmacol Exp Ther}^{. 2010 Jan;332(1):35-45} ^{Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells.} ^{Antoon JW, Liu J, Gestaut MM, Burow ME, Beckman BS, Foroozesh M.} ^{J Med Chem}^{. 2009 Sep 24;52(18):5748-52.} ^{Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence.} ^{Rhodes LV, Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P, Tilghman SL, Salvo VA, Fonseca JP, Lacey MR, Beckman BS, McLachlan JA, Rowan BG, Pochampally R, Burow ME.} ^{Breast Cancer Res Treat}^{. 2010 Jun;121(2):293-300} ^{Sphingolipids as determinants of apoptosis and chemoresistance in the MCF-7 cell model system.} ^{Meacham WD, Antoon JW, Burow ME, Struckhoff AP, Beckman BS.} ^{Exp Biol Med (Maywood)}^{. 2009 Nov;234(11):1253-63.} ^{Phytoalexin-enriched functional foods.} ^{Boue SM, Cleveland TE, Carter-Wientjes C, Shih BY, Bhatnagar D, McLachlan JM, Burow ME.} ^{J Agric Food Chem}^{. 2009 Apr 8;57(7):2614-22.} ^{Molecular effects of soy phytoalexin glyceollins in human prostate cancer cells LNCaP.} ^{Payton-Stewart F, Schoene NW, Kim YS, Burow ME, Cleveland TE, Boue SM, Wang TT.} ^{Mol Carcinog}^{. 2009 Sep;48(9):862-71.} ^{Human uterine smooth muscle and leiomyoma cells differ in their rapid 17beta-estradiol signaling: implications for proliferation.} ^{Nierth-Simpson EN, Martin MM, Chiang TC, Melnik LI, Rhodes LV, Muir SE, Burow ME, McLachlan JA.} ^{Identification of the potent phytoestrogen glycinol in elicited soybean (Glycine max).} ^{Boué SM, Tilghman SL, Elliott S, Zimmerman MC, Williams KY, Payton-Stewart F, Miraflor AP, Howell MH, Shih BY, Carter-Wientjes CH, Segar C, Beckman BS, Wiese TE, Cleveland TE, McLachlan JA, Burow ME.} ^{Endocrinology}^{. 2009 May;150(5):2446-53.} ^{Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype.} ^{Zhou C, Nitschke AM, Xiong W, Zhang Q, Tang Y, Bloch M, Elliott S, Zhu Y, Bazzone L, Yu D, Weldon CB, Schiff R, McLachlan JA, Beckman BS, Wiese TE, Nephew KP, Shan B, Burow ME, Wang G.} ^{Breast Cancer Res}^{. 2008;10(6):R105.} ^{Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis.} ^{Li Z, Carrier L, Belame A, Thiyagarajah A, Salvo VA, Burow ME, Rowan BG.} ^{Breast Cancer Res Treat}^{. 2009 Nov;118(1):33-43.} ^{Organochlorine-mediated potentiation of the general coactivator p300 through p38 mitogen-activated protein kinase.} ^{Bratton MR, Frigo DE, Vigh-Conrad KA, Fan D, Wadsworth S, McLachlan JA, Burow ME.} ^{Detecting ligands and dissecting nuclear receptor-signaling pathways using recombinant strains of the yeast Saccharomyces cerevisiae.} ^{Fox JE, Burow ME, McLachlan JA, Miller CA 3rd.} ^{Nat Protoc}^{. 2008;3(4):637-45.} ^{Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat Toxoplasma gondii and Encephalitozoon cuniculi infection.} ^{Wei S, Daniel BJ, Brumlik MJ, Burow ME, Zou W, Khan IA, Wadsworth S, Siekierka J, Curiel TJ.} ^{Antimicrob Agents Chemother}^{. 2007 Dec;51(12):4324-8.} ^{Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression.} ^{Tang Y, Zhao DY, Elliott S, Zhao W, Curiel TJ, Beckman BS, Burow ME.} ^{Int J Oncol}^{. 2007 Oct;31(4):705-11.} ^{Pesticides reduce symbiotic efficiency of nitrogen-fixing rhizobia and host plants.} ^{Fox JE, Gulledge J, Engelhaupt E, Burow ME, McLachlan JA.} ^{Proc Natl Acad Sci U S A}^{. 2007 Jun 12;104(24):10282-7} ^{Effects of soybean glyceollins and estradiol in postmenopausal female monkeys.} ^{Wood CE, Clarkson TB, Appt SE, Franke AA, Boue SM, Burow ME, McCoy T, Cline JM.} ^{Nutr Cancer}^{. 2006;56(1):74-81.} ^{Toxoplasma gondii expresses two mitogen-activated protein kinase genes that represent distinct protozoan subfamilies.} ^{Lacey MR, Brumlik MJ, Yenni RE, Burow ME, Curiel TJ.} ^{J Mol Evol}^{. 2007 Jan;64(1):4-14.} ^{Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis.} ^{Salvo VA, Boué SM, Fonseca JP, Elliott S, Corbitt C, Collins-Burow BM, Curiel TJ, Srivastav SK, Shih BY, Carter-Wientjes C, Wood CE, Erhardt PW, Beckman BS, McLachlan JA, Cleveland TE, Burow ME.} ^{Clin Cancer Res}^{. 2006 Dec 1;12(23):7159-64} ^{AKT regulation of estrogen receptor beta transcriptional activity in breast cancer.} ^{Duong BN, Elliott S, Frigo DE, Melnik LI, Vanhoy L, Tomchuck S, Lebeau HP, David O, Beckman BS, Alam J, Bratton MR, McLachlan JA, Burow ME.} ^{Cancer Res}^{. 2006 Sep 1;66(17):8373-81.} ^{p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1.} ^{Frigo DE, Basu A, Nierth-Simpson EN, Weldon CB, Dugan CM, Elliott S, Collins-Burow BM, Salvo VA, Zhu Y, Melnik LI, Lopez GN, Kushner PJ, Curiel TJ, Rowan BG, McLachlan JA, Burow ME.} ^{Mol Endocrinol}^{. 2006 May;20(5):971-83} ^{Macrophage migration inhibitory factor: a central regulator of wound healing.} ^{Hardman MJ, Waite A, Zeef L, Burow M, Nakayama T, Ashcroft GS.} ^{Am J Pathol}^{. 2005 Dec;167(6):1561-74.} ^{Differential regulation of estrogen receptor alpha, glucocorticoid receptor and retinoic acid receptor alpha transcriptional activity by melatonin is mediated via different G proteins.} ^{Kiefer TL, Lai L, Yuan L, Dong C, Burow ME, Hill SM.} ^{J Pineal Res}^{. 2005 May;38(4):231-9.} ^{PKC-mediated survival signaling in breast carcinoma cells: a role for MEK1-AP1 signaling.} ^{Weldon CB, McKee A, Collins-Burow BM, Melnik LI, Scandurro AB, McLachlan JA, Burow ME, Beckman BS.} ^{Int J Oncol}^{. 2005 Mar;26(3):763-8.} ^{Xenobiotic-induced TNF-alpha expression and apoptosis through the p38 MAPK signaling pathway.} ^{Frigo DE, Vigh KA, Struckhoff AP, Elliott S, Beckman BS, Burow ME, McLachlan JA.} ^{Toxicol Lett}^{. 2005 Feb 15;155(2):227-38.} ^{The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone.} ^{Williams CC, Allison JG, Vidal GA, Burow ME, Beckman BS, Marrero L, Jones FE.} ^{J Cell Biol}^{. 2004 Nov 8;167(3):469-78.} ^{Identification of a novel mitogen-activated protein kinase in Toxoplasma gondii.} ^{Brumlik MJ, Wei S, Finstad K, Nesbit J, Hyman LE, Lacey M, Burow ME, Curiel TJ.} ^{Int J Parasitol}^{. 2004 Oct;34(11):1245-54.} ^{Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.} ^{Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W.} ^{Nat Med}^{. 2004 Sep;10(9):942-9. Epub 2004 Aug 22.} ^{Regulation of estrogen-mediated cell survival and proliferation by p160 coactivators.} ^{Weldon CB, Elliott S, Zhu Y, Clayton JL, Curiel TJ, Jaffe BM, Burow ME.} ^Surgery^{. 2004 Aug;136(2):346-54.} ^{Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling.} ^{Weldon CB, Parker AP, Patten D, Elliott S, Tang Y, Frigo DE, Dugan CM, Coakley EL, Butler NN, Clayton JL, Alam J, Curiel TJ, Beckman BS, Jaffe BM, Burow ME.} ^{Int J Oncol}^{. 2004 Jun;24(6):1473-80.} ^{Phytoestrogen signaling and symbiotic gene activation are disrupted by endocrine-disrupting chemicals.} ^{Fox JE, Starcevic M, Jones PE, Burow ME, McLachlan JA.} ^{Environ Health Perspect}^{. 2004 May;112(6):672-7.} ^{Novel ceramide analogs as potential chemotherapeutic agents in breast cancer.} ^{Struckhoff AP, Bittman R, Burow ME, Clejan S, Elliott S, Hammond T, Tang Y, Beckman BS.} ^{J Pharmacol Exp Ther}^{. 2004 May;309(2):523-32. Epub 2004 Jan 23.} ^{Mechanism of AP-1-mediated gene expression by select organochlorines through the p38 MAPK pathway.} ^{Frigo DE, Tang Y, Beckman BS, Scandurro AB, Alam J, Burow ME, McLachlan JA.} ^{Carcinogenesis}^{. 2004 Feb;25(2):249-61} ^{Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system.} ^{Simstein R, Burow M, Parker A, Weldon C, Beckman B.} ^{Exp Biol Med (Maywood)}^{. 2003 Oct;228(9):995-1003. Review.} ^{Symbiotic gene activation is interrupted by endocrine disrupting chemicals.} ^{Fox JE, Burow ME, McLachlan JA.} ^{ScientificWorldJournal}^{. 2001 Nov 13;1:653-5. Review.} ^{Estrogen modulates cutaneous wound healing by downregulating macrophage migration inhibitory factor.} ^{Ashcroft GS, Mills SJ, Lei K, Gibbons L, Jeong MJ, Taniguchi M, Burow M, Horan MA, Wahl SM, Nakayama T.} ^{J Clin Invest}^{. 2003 May;111(9):1309-18.} ^{Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.} ^{Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, David O, Burow M, Gordon A, Dhurandhar N, Myers L, Berggren R, Hemminki A, Alvarez RD, Emilie D, Curiel DT, Chen L, Zou W.} ^{Nat Med}^{. 2003 May;9(5):562-7. Epub 2003 Apr 21.} ^{Evaluation of the estrogenic effects of legume extracts containing phytoestrogens.} ^{Boué SM, Wiese TE, Nehls S, Burow ME, Elliott S, Carter-Wientjes CH, Shih BY, McLachlan JA, Cleveland TE.} ^{J Agric Food Chem}^{. 2003 Apr 9;51(8):2193-9.} ^{NF-kappaB plays a key role in hypoxia-inducible factor-1-regulated erythropoietin gene expression.} ^{Figueroa YG, Chan AK, Ibrahim R, Tang Y, Burow ME, Alam J, Scandurro AB, Beckman BS.} ^{Exp Hematol}^{. 2002 Dec;30(12):1419-27.} ^{DDT and its metabolites alter gene expression in human uterine cell lines through estrogen receptor-independent mechanisms.} ^{Frigo DE, Burow ME, Mitchell KA, Chiang TC, McLachlan JA.} ^{Environ Health Perspect}^{. 2002 Dec;110(12):1239-45.} ^{Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray.} ^{Weldon CB, Scandurro AB, Rolfe KW, Clayton JL, Elliott S, Butler NN, Melnik LI, Alam J, McLachlan JA, Jaffe BM, Beckman BS, Burow ME.} ^Surgery^{. 2002 Aug;132(2):293-301.} ^{Flavonoid phytochemicals regulate activator protein-1 signal transduction pathways in endometrial and kidney stable cell lines.} ^{Frigo DE, Duong BN, Melnik LI, Schief LS, Collins-Burow BM, Pace DK, McLachlan JA, Burow ME.} ^{J Nutr}^{. 2002 Jul;132(7):1848-53.} ^{Silica-induced apoptosis in murine macrophage: involvement of tumor necrosis factor-alpha and nuclear factor-kappaB activation.} ^{Gozal E, Ortiz LA, Zou X, Burow ME, Lasky JA, Friedman M.} ^{Am J Respir Cell Mol Biol}^{. 2002 Jul;27(1):91-8.} ^{Promoter CpG methylation of Hox-a10 and Hox-a11 in mouse uterus not altered upon neonatal diethylstilbestrol exposure.} ^{Li S, Ma L, Chiang T, Burow M, Newbold RR, Negishi M, Barrett JC, McLachlan JA.} ^{Mol Carcinog}^{. 2001 Dec;32(4):213-9.} ^{Oestrogen-mediated suppression of tumour necrosis factor alpha-induced apoptosis in MCF-7 cells: subversion of Bcl-2 by anti-oestrogens.} ^{Burow ME, Weldon CB, Tang Y, McLachlan JA, Beckman BS.} ^{J Steroid Biochem Mol Biol}^{. 2001 Nov;78(5):409-18.} ^{Endocrine disruption in sexual differentiation and puberty. What do pseudohermaphroditic polar bears have to do with the practice of pediatrics?} ^{Gulledge CC, Burow ME, McLachlan JA.} ^{Pediatr Clin North Am}^{. 2001 Oct;48(5):1223-40, x. Review.} ^{Nitrogen fixation. Endocrine disrupters and flavonoid signalling.} ^{Fox JE, Starcevic M, Kow KY, Burow ME, McLachlan JA.} ^Nature^{. 2001 Sep 13;413(6852):128-9.} ^{Estrogenic and antiestrogenic activities of flavonoid phytochemicals through estrogen receptor binding-dependent and -independent mechanisms.} ^{Collins-Burow BM, Burow ME, Duong BN, McLachlan JA.} ^{Nutr Cancer}^{. 2000;38(2):229-44.} ^{NF-kappa B-mediated chemoresistance in breast cancer cells.} ^{Weldon CB, Burow ME, Rolfe KW, Clayton JL, Jaffe BM, Beckman BS.} ^Surgery^{. 2001 Aug;130(2):143-50.} ^{From malformations to molecular mechanisms in the male: three decades of research on endocrine disrupters.} ^{McLachlan JA, Newbold RR, Burow ME, Li SF.} ^APMIS^{. 2001 Apr;109(4):263-72. Review.} ^{Effects of estrogen on leptin gene promoter activation in MCF-7 breast cancer and JEG-3 choriocarcinoma cells: selective regulation via estrogen receptors alpha and beta.} ^{O’Neil JS, Burow ME, Green AE, McLachlan JA, Henson MC.} ^{Mol Cell Endocrinol}^{. 2001 May 15;176(1-2):67-75.} ^{Gene imprinting in developmental toxicology: a possible interface between physiology and pathology.} ^{McLachlan JA, Burow M, Chiang TC, Li SF.} ^{Toxicol Lett}^{. 2001 Mar 31;120(1-3):161-4. Review.} ^{Phytochemical glyceollins, isolated from soy, mediate antihormonal effects through estrogen receptor alpha and beta.} ^{Burow ME, Boue SM, Collins-Burow BM, Melnik LI, Duong BN, Carter-Wientjes CH, Li S, Wiese TE, Cleveland TE, McLachlan JA.} ^{J Clin Endocrinol Metab}^{. 2001 Apr;86(4):1750-8.} ^{Mechanism of heme oxygenase-1 gene activation by cadmium in MCF-7 mammary epithelial cells. Role of p38 kinase and Nrf2 transcription factor.} ^{Alam J, Wicks C, Stewart D, Gong P, Touchard C, Otterbein S, Choi AM, Burow ME, Tou J.} ^{J Biol Chem}^{. 2000 Sep 8;275(36):27694-702.} ^{Differences in protein kinase C and estrogen receptor alpha, beta expression and signaling correlate with apoptotic sensitivity of MCF-7 breast cancer cell variants.} ^{Burow ME, Weldon CB, Chiang TC, Tang Y, Collins-Burow BM, Rolfe K, Li S, McLachlan JA, Beckman BS.} ^{Int J Oncol}^{. 2000 Jun;16(6):1179-87.} ^{PI3-K/AKT regulation of NF-kappaB signaling events in suppression of TNF-induced apoptosis.} ^{Burow ME, Weldon CB, Melnik LI, Duong BN, Collins-Burow BM, Beckman BS, McLachlan JA.} ^{Biochem Biophys Res Commun}^{. 2000 May 10;271(2):342-5.} ^{Cross-talk between phosphatidylinositol 3-kinase and sphingomyelinase pathways as a mechanism for cell survival/death decisions.} ^{Burow ME, Weldon CB, Collins-Burow BM, Ramsey N, McKee A, Klippel A, McLachlan JA, Clejan S, Beckman BS.} ^{J Biol Chem}^{. 2000 Mar 31;275(13):9628-35.} ^{Effects of cadmium cell viability, trophoblastic development, and expression of low density lipoprotein receptor transcripts in cultured human placental cells.} ^{Jolibois LS Jr, Burow ME, Swan KF, George WJ, Anderson MB, Henson MC.} ^{Reprod Toxicol}^{. 1999 Nov-Dec;13(6):473-80.} ^{Effects of environmental estrogens on tumor necrosis factor alpha-mediated apoptosis in MCF-7 cells.} ^{Burow ME, Tang Y, Collins-Burow BM, Krajewski S, Reed JC, McLachlan JA, Beckman BS.} ^{Carcinogenesis}^{. 1999 Nov;20(11):2057-61} ^{Differences in susceptibility to tumor necrosis factor alpha-induced apoptosis among MCF-7 breast cancer cell variants.} ^{Burow ME, Weldon CB, Tang Y, Navar GL, Krajewski S, Reed JC, Hammond TG, Clejan S, Beckman BS.} ^{Cancer Res}^{. 1998 Nov 1;58(21):4940-6.}

Recent Posts

Recent Comments

Archives

Categories

Meta